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LETTER TO THE EDITOR
A possible role for leukotriene B4 in head and neck cancer
Sir - Leukotriene B4 (LTB4) formed through 5-
lipoxygenation of arachidonic acid shows potent biological
actions aligned to the high incidence of immunological
deficiencies and inflammatory symptoms associated with
human head and neck cancer (Papenhausen et al., 1979;
Bray, 1983). Although homogenates of human squamous cell
carcinomas (HSCC) contain 5, 12 and 15 hydroxy-
eicosatetraenoic acids the presence of LTS has yet to be
established (El-Attar et al., 1985).
Tumour tissue was obtained from the cheek pouch of nine
Syrian hamsters after 12 weeks of three applications of
dimethylbenzanthracene (DMBA 0.5% in mineral oil) per
week as previously described (Eveson, 1981). Animals
painted with vehicle alone served as controls. Human studies
were carried out in cancerous and unaffected control tissue
from eight patients undergoing resection for squamous cell
carcinoma of the head and neck. Clinical indices were
routinely measured and previous treatments recorded.
Each tissue was extracted in ice-cold ethanol (80%) in the
presence of 3H-LTB4 (2nCi, 32Cimmol-1) for recovery
estimation. Samples were then purified by reverse-phase high
performance liquid chromatography (Mathews et al., 1981)
and LTB4 was measured by specific radioimmunoassay using
a double antibody technique (Hayes et al., 1983).
Our results (Table I) show the presence of LTB4-ir in
animal and HSCC in amounts similar to that observed for
other arachidonic acid metabolites, of which prostaglandin
E2 (PGE2) has received much attention (Porteder et al.,
1984). A likely source of LTB4 could be inflammatory or
malignant cells.
The effects of 5-lipoxygenase products on tumour biology
are not well understood but a role for LTB4 as a mediator
of inflammation (Ford-Hutchinson et al., 1980), and
immunoregulation (Rola-Pleszczynski & Sirios, 1983) has
been proposed. In the inflammatory response, LTB4 stimu-
lates increased vascular permeability and oedema responses
particularly in the presence of vasodilator substances such as
PGE2 (Wedmore & Williams, 1980). LTB4 significantly
inhibits human mitogen-induced lymphocyte proliferation in
vitro probably provided through PGE2 release leading to
Table I Measurement of LTB4 immunoreactivity in squamous cell
carcinoma of the oral cavity
Hamster Human
Unaffected
Control Tumour tissue Tumour
(n= 10) (n=9) * (n=8)
Tissue
weight (g) 0.06+0.04 0.5+0.07 0.04+0.14 0.04+0.08
LTB4-ir
(ngg1) 0.05+0.3 14.7+4.Oa 1.5+ 1.0 17.6+5.9b
Recovery (%) 52.8+6.0 43.0+3.0 53.3+7.1 46.0+5.8
aP<0.01 compared with control values (Wilcoxon unpaired rank
sum test).
bp<0.05 compared with unaffected tissue (Wilcoxon paired rank
sum test).
immunosuppression (Rola-Pleszczynski & Sirios, 1983) and
as patients with head and neck cancer show a low level of
immune competence this may be important.
The observation that LTs can protect cancerous tissue
against radiation therapy could have pathogenic and clinical
implications (Hansen, 1987). If LTB4 does play a role in the
pathogenesis of head and neck cancer, the effects of pharma-
cological modification of its actions should be
evaluated. Yours etc.,
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